Access the full text.
Sign up today, get DeepDyve free for 14 days.
Jennifer Robinson, B. Nedergaard, W. Rogers, J. Fialkow, J. Neutel, David Ramstad, R. Somaratne, J. Legg, Patric Nelson, R. Scott, S. Wasserman, R. Weiss (2014)
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.JAMA, 311 18
D. Blom, T. Hála, M. Bolognese, M. Lillestol, P. Toth, L. Burgess, R. Češka, E. Roth, M. Koren, C. Ballantyne, M. Monsalvo, Kate Tsirtsonis, Jae Kim, R. Scott, S. Wasserman, E. Stein (2014)
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.The New England journal of medicine, 370 19
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, L. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly (1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The New England journal of medicine, 339 19
S. Ebrahim, F. Taylor, P. Brindle (2014)
Statins for the primary prevention of cardiovascular diseaseBMJ : British Medical Journal, 348
A. Olsson, J. Mcmurray, G. Thorgeirsson, C. Spaulding, J. Slattery, K. Pyörälä, O. Faergeman, R. Wright, Kåre Berg, L. Wilhelmsen, T. Pedersen, T. Miettinen, H. White, J. Kjekshus, M. Gnant (1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.Atherosclerosis. Supplements, 5 3
Genaro Fernandez, E. Spatz, C. Jablecki, P. Phillips (2011)
Statin myopathy: A common dilemma not reflected in clinical trialsCleveland Clinic Journal of Medicine, 78
(2011)
ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Eur Heart J, 32
V. Roger, A. Go, D. Lloyd‐Jones, R. Adams, J. Berry, T. Brown, M. Carnethon, S. Dai, G. Simone, E. Ford, C. Fox, H. Fullerton, C. Gillespie, K. Greenlund, S. Hailpern, J. Heit, P. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, J. Lichtman, L. Lisabeth, D. Makuc, G. Marcus, A. Marelli, D. Matchar, M. McDermott, J. Meigs, C. Moy, D. Mozaffarian, M. Mussolino, G. Nichol, N. Paynter, W. Rosamond, P. Sorlie, R. Stafford, T. Turan, M. Turner, N. Wong, J. Wylie-Rosett (2011)
Heart disease and stroke statistics--2011 update: a report from the American Heart Association.Circulation, 123 4
J. Downs, M. Clearfield, S. Weis, E. Whitney, D. Shapiro, P. Beere, A. Langendorfer, E. Stein, W. Kruyer, A. Gotto (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA, 279 20
S. Ebrahim, J. Casas (2012)
Statins for all by the age of 50 years?The Lancet, 380
N. Seidah, Z. Awan, M. Chrétien, M. Mbikay (2014)
PCSK9: A Key Modulator of Cardiovascular HealthCirculation Research, 114
J. Ansquer, R. Dalton, E. Caussé, D. Crimet, K. Malicot, C. Foucher (2008)
Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.American journal of kidney diseases : the official journal of the National Kidney Foundation, 51 6
S. Feasson (2008)
MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.
M. Alberton, Ping Wu, E. Druyts, Matthias Briel, Edward Mills (2012)
Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.QJM : monthly journal of the Association of Physicians, 105 2
Siddharth Singh, A. Singh, Preet Singh, M. Murad, P. Iyer (2013)
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 11 6
M. Flather (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
D. Fedder, C. Koro, G. L’italien (2002)
New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid-Lowering Drug Therapy: Projected Impact on the Size, Sex, and Age Distribution of the Treatment-Eligible PopulationCirculation: Journal of the American Heart Association, 105
横山 光宏, R. Ross (1998)
Atherosclerosis is an Inflammatory DiseaseJapanese Circulation Journal-english Edition, 62
I. Hamilton‐Craig, K. Kostner, D. Colquhoun, S. Woodhouse (2010)
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemiaVascular Health and Risk Management, 6
M. Guerin, Éric Bruckert, P. Dolphin, G. Turpin, M. Chapman (1996)
Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.Arteriosclerosis, thrombosis, and vascular biology, 16 6
C. Gagné, H. Bays, S. Weiss, P. Mata, K. Quinto, M. Melino, Meehyung Cho, T. Musliner, B. Gumbiner (2002)
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.The American journal of cardiology, 90 10
M. Dewood, J. Spores, G. Hensley, C. Simpson, Eugster Gs, Sutherland Ki, R. Grunwald, J. Shields (1983)
Coronary arteriographic findings in acute transmural myocardial infarction.Circulation, 68 2 Pt 2
Qiying Fan, Xing Yin, Abeer Rababa’h, Andrea Diaz, Cori Wijaya, Sonal Singh, Santosh Suryavanshi, H. Vo, Moawiz Saeed, Yang Zhang, B. McConnell (2019)
Absence of Gravin Mediated Signaling Inhibits Development of High Fat Diet-Induced Hyperlipidemia and Atherosclerosis.American journal of physiology. Heart and circulatory physiology
(2013)
FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury
Siddharth Singh, Preet Singh, A. Singh, M. Murad, W. Sanchez (2013)
Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis.Gastroenterology, 144 2
M. Lorenz, J. Polak, M. Kavousi, E. Mathiesen, H. Völzke, T. Tuomainen, D. Sander, Matthieu Plichart, A. Catapano, C. Robertson, S. Kiechl, T. Rundek, M. Desvarieux, L. Lind, Carolin Schmid, P. DasMahapatra, Lu Gao, K. Ziegelbauer, M. Bots, S. Thompson (2012)
Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant dataThe Lancet, 379
K. Sakakura, M. Nakano, F. Otsuka, E. Ladich, F. Kolodgie, R. Virmani (2013)
Pathophysiology of atherosclerosis plaque progression.Heart, lung & circulation, 22 6
Peter Jones, Radhika Nair, K. Thakker (2012)
Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective AnalysisJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 1
P. Toth, M. Davidson (2005)
Cholesterol absorption blockade with ezetimibe.Current drug targets. Cardiovascular & haematological disorders, 5 6
D. Wood, G. Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä (1998)
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.Atherosclerosis, 140 2
S. Lewis (2011)
Lipid-lowering therapy: who can benefit?Vascular Health and Risk Management, 7
(2013)
and Drug Administration
P. Sever, B. Dahlöf, N. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S. Kjeldsen, A. Kristinsson, G. Mcinnes, J. Mehlsen, M. Nieminen, E. O’Brien, J. Östergren (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialThe Lancet, 361
E. Bruckert, G. Hayem, S. Dejager, C. Yau, B. Bégaud (2005)
Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO StudyCardiovascular Drugs and Therapy, 19
W. Howard (2007)
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyYearbook of Endocrinology, 2007
(2014)
2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol, 63
(Taylor F, Huffman MD, Macedo AF, Moore T, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1(1).)
Taylor F, Huffman MD, Macedo AF, Moore T, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1(1).Taylor F, Huffman MD, Macedo AF, Moore T, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1(1)., Taylor F, Huffman MD, Macedo AF, Moore T, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1(1).
S. Tuteja, N. Pyrsopoulos, W. Wolowich, Kamran Khanmoradi, D. Levi, G. Selvaggi, G. Weisbaum, A. Tzakis, E. Schiff (2008)
Simvastatin‐Ezetimibe‐Induced Hepatic Failure Necessitating Liver TransplantationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 28
M. Sabatine, R. Giugliano, A. Keech, Narimon Honarpour, S. Wiviott, S. Murphy, J. Kuder, Huei Wang, Thomas Liu, S. Wasserman, P. Sever, T. Pedersen (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseThe New England Journal of Medicine, 376
G. Savarese, A. Gotto, S. Paolillo, C. D’Amore, T. Losco, F. Musella, O. Scala, C. Marcianò, Donatella Ruggiero, F. Marsico, G. Luca, B. Trimarco, P. Perrone-filardi (2013)
Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis.Journal of the American College of Cardiology, 62 22
Richard Pasternak, Sidney Smith, C. Bairey-Merz, Scott Grundy, J. Cleeman, C. Lenfant (2002)
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.Stroke, 33 9
(Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.)
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22., Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.
A. Tenenbaum, M. Motro, E. Fisman, D. Tanné, V. Boyko, S. Behar (2005)
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.Archives of internal medicine, 165 10
J. Ambrose, S. Winters, R. Arora, J. Haft, J. Goldstein, K. Rentrop, R. Gorlin, V. Fuster (1985)
Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction.Journal of the American College of Cardiology, 6 6
Deren Wang, Bian Liu, W. Tao, Z. Hao, Ming Liu (2015)
Fibrates for secondary prevention of cardiovascular disease and stroke.The Cochrane database of systematic reviews, 10
C. Baigent, L. Blackwell, J. Emberson, L. Holland, C. Reith, N. Bhala, R. Peto, E. Barnes, A. Keech, J. Simes, R. Collins (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsLancet, 376
J. Shepherd, A. Gaw (2002)
The Anatomy of a Clinical TrialMedical Principles and Practice, 11
J. Horton, Jonathan Cohen, H. Hobbs (2009)
PCSK9: a convertase that coordinates LDL catabolism Published, JLR Papers in Press, November 19, 2008.Journal of Lipid Research, 50
M. Abifadel, M. Varret, J. Rabès, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, A. Derré, Ludovic Villéger, M. Farnier, I. Beucler, E. Bruckert, J. Chambaz, B. Chanu, J. Lecerf, G. Luc, P. Moulin, J. Weissenbach, Annick Prat, M. Krempf, C. Junien, N. Seidah, C. Boileau (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 34
(2002)
Detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final reportNatl Heart Lung Blood Inst, 106
N. Wenger, S. Lewis, D. Herrington, V. Bittner, F. Welty (2007)
Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart DiseaseAnnals of Internal Medicine, 147
R. Knopp, H. Gitter, T. Truitt, Harold Bays, C. Manion, L. Lipka, A. Lebeaut, Ramachandran Suresh, Bo Yang, E. Veltri (2003)
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.European heart journal, 24 8
D. Lopez (2008)
PCSK9: an enigmatic protease.Biochimica et biophysica acta, 1781 4
R. Pasternak, Sidney Smith, C. Bairey-Merz, S. Grundy, J. Cleeman, C. Lenfant (2002)
ACC/AHA/NHLBI clinical advisory on the use and safety of statins.Journal of the American College of Cardiology, 40 3
J. Bentzon, F. Otsuka, R. Virmani, E. Falk (2014)
Mechanisms of Plaque Formation and Rupture
G. Savarese, F. Musella, M. Volpe, F. Paneni, P. Perrone-filardi (2013)
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.International journal of cardiology, 167 6
F. Sacks, M. Pfeffer, L. Moye, J. Rouleau, J. Rutherford, T. Cole, L. Brown, J. Warnica, J. Arnold, C. Wun, B. Davis, E. Braunwald (1996)
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.The New England journal of medicine, 335 14
L. Berthou, R. Saladin, P. Yaqoob, Didier Branellec, Philip Calder, J. Fruchart, Patrice Denefle, Johan Auwerx, Bart Staels (1995)
Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids.European journal of biochemistry, 232 1
R. Birjmohun, B. Hutten, J. Kastelein, E. Stroes (2005)
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.Journal of the American College of Cardiology, 45 2
A. Nordmann, I. Ferreira-González, B. Kasenda, R. Saccilotto, D. Bassler, N. Bhatnagar, M. Briel (2016)
Fibrates for primary prevention of cardiovascular disease events.The Cochrane database of systematic reviews, 3
J. Shepherd, S. Cobbe, I. Ford, C. Isles, A. Lorimer, P. Macfarlane, J. Mckillop, C. Packard (1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemiaThe New England Journal of Medicine, 333
Alberico Catapano, Željko Reiner, Guy Backer, Ian Graham, M. Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegría, M. Chapman, P. Durrington, S. Erdine, Julian Halcox, Richard Hobbs, J. Kjekshus, Pasquale Filardi, G. Riccardi, Robert Storey, David Wood (2011)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis, 217 Suppl 1
P. Shah (2003)
Mechanisms of plaque vulnerability and rupture.Journal of the American College of Cardiology, 41 4 Suppl S
S. Grundy, D. Becker, L. Clark, R. Cooper, M. Denke, James Howard, D. Hunninghake, D. Illingworth, R. Luepker, P. Mcbride, J. Mckenney, R. Pasternak, N. Stone, L. Horn, H. Brewer, J. Cleeman, N. Ernst, D. Gordon, D. Levy, B. Rifkind, J. Rossouw, P. Savage, S. Haffner, D. Orloff, M. Proschan, J. Schwartz, C. Sempos, Susan Shero, Elaine Murray, Susan Keller, Angela Jehle, T. Ganiats, Gary Graham (2015)
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Krista Dale, C. Coleman, Nickole Henyan, J. Kluger, C. White (2006)
Statins and cancer risk: a meta-analysis.JAMA, 295 1
(1998)
The Care Investigators, Cardiol Ther
A. Keech, R. Simes, P. Barter, J. Best, Russel Scott, M. Taskinen, P. Forder, Avinesh Pillai, T. Davis, P. Glasziou, P. Drury, Kesäniemi Ya, D. Sullivan, D. Hunt, P. Colman, M. d’Emden, M. Whiting, C. Ehnholm, M. Laakso (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialThe Lancet, 366
S. Yusuf, S. Hawken, S. Ôunpuu, T. Dans, Á. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, Li-sheng Liu (2004)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 364
H. Rubins, S. Robins, D. Collins, C. Fye, James Anderson, M. Elam, F. Faas, E. Linares, E. Schaefer, G. Schectman, T. Wilt, J. Wittes (1999)
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.The New England journal of medicine, 341 6
E. Benjamin, S. Virani, C. Callaway, A. Chamberlain, Alexander Chang, Susan Cheng, Stephanie Chiuve, M. Cushman, F. Delling, R. Deo, S. Ferranti, J. Ferguson, M. Fornage, C. Gillespie, C. Isasi, M. Jimenez, L. Jordan, S. Judd, D. Lackland, J. Lichtman, L. Lisabeth, Simin Liu, C. Longenecker, P. Lutsey, J. Mackey, D. Matchar, K. Matsushita, M. Mussolino, K. Nasir, M. O’Flaherty, L. Palaniappan, A. Pandey, D. Pandey, M. Reeves, M. Ritchey, C. Rodriguez, Gregory Roth, W. Rosamond, Uchechukwu Sampson, G. Satou, Svati Shah, Nicole Spartano, D. Tirschwell, C. Tsao, Jenifer Voeks, J. Willey, J. Wilkins, Jason Wu, Heather Alger, Sally Wong, P. Muntner (2018)
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart AssociationCirculation, 137
P. Morris, C. Ballantyne, K. Birtcher, S. Dunn, E. Urbina (2014)
Review of clinical practice guidelines for the management of LDL-related risk.Journal of the American College of Cardiology, 64 2
S. Mali, Hasan Haghaninejad (2019)
Pulmonary complications following cardiac surgeryArchives of Medical Sciences. Atherosclerotic Diseases, 4
A. Kashani, T. Sallam, Swarna Bheemreddy, D. Mann, Yun Wang, J. Foody (2008)
Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.The American journal of cardiology, 101 11
(2004)
El tratamiento hipolipemiante intensivo frente al moderado con estatinas tras síndromes coronarios agudos
M. Stolk, M. Becx, K. Kuypers, C. Seldenrijk (2006)
Severe hepatic side effects of ezetimibe.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 4 7
S. Fazio, M. Linton (2004)
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacyCurrent Atherosclerosis Reports, 6
J. Robson (2007)
Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular diseaseHeart, 94
H. Naci, J. Brugts, T. Ades (2013)
Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled TrialsCirculation: Cardiovascular Quality and Outcomes, 6
J. Emberson, P. Kearney, L. Blackwell, C. Newman, C. Reith, N. Bhala, L. Holland, R. Peto, A. Keech, R. Collins, J. Simes, C. Baigent (2012)
Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin TherapyPLoS ONE, 7
P. Sever, C. Chang, Ajay Gupta, A. Whitehouse, N. Poulter (2011)
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.European heart journal, 32 20
H. Ogawa (1999)
[Pathophysiology of acute coronary syndromes].Journal of cardiology, 33 Suppl 1
Huabing Zhang, J. Plutzky, S. Skentzos, F. Morrison, Perry Mar, M. Shubina, A. Turchin (2013)
Accuracy of Electronically Reported “Meaningful Use” Clinical Quality MeasuresAnnals of Internal Medicine, 159
J. Castellote, J. Ariza, R. Rota, A. Girbau, X. Xiol (2008)
Serious drug-induced liver disease secondary to ezetimibe.World journal of gastroenterology, 14 32
R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto (2003)
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialThe Lancet, 361
J. Shepherd, G. Blauw, M. Murphy, E. Bollen, B. Buckley, S. Cobbe, I. Ford, A. Gaw, M. Hyland, J. Jukema, A. Kamper, P. Macfarlane, A. Meinders, J. Norrie, C. Packard, I. Perry, D. Stott, Brian Sweeney, Gillian Twomey, R. Westendorp (2002)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialThe Lancet, 360
P. Deedwania, P. Barter, R. Carmena, J. Fruchart, S. Grundy, Steven Haffner, J. Kastelein, J. Larosa, H. Schachner, J. Shepherd, D. Waters (2006)
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyThe Lancet, 368
(2011)
European Association for Cardiovascular Prevention
(2001)
Fibrate treatment can increase serum creatinine levelsAtheroscler Suppl, 2
R. Peto, J. Emberson, M. Landray, C. Baigent, R. Collins, R. Clare, R. Califf (2008)
Analyses of cancer data from three ezetimibe trials.The New England journal of medicine, 359 13
R. Goldberg, M. Mellies, F. Sacks, L. Moye, B. Howard, W. Howard, B. Davis, T. Cole, M. Pfeffer, E. Braunwald (1998)
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.Circulation, 98 23
J. Desager, Y. Horsmans, C. Vandenplas, C. Harvengt (1996)
Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.Atherosclerosis, 124 Suppl
Jane Thomas, S. Paranjothy, D. James (2004)
National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean sectionBMJ : British Medical Journal, 328
(2004)
Intensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med, 350
R. Bhopal, N. Unwin, M. White, J. Yallop, L. Walker, K. Alberti, J. Harland, S. Patel, Naseer Ahmad, C. Turner, Bill Watson, Dalvir Kaur, Annarao Kulkarni, M. Laker, A. Tavridou (1999)
Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional studyBMJ, 319
Moutzouri, A. Kei, M. Elisaf, H. Milionis (2010)
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
Williams Kj, I. Tabas (1999)
Atherosclerosis--an inflammatory disease.The New England journal of medicine, 340 24
M. Koren, Pernille Lundqvist, M. Bolognese, J. Neutel, M. Monsalvo, Jingyuan Yang, Jae Kim, R. Scott, S. Wasserman, H. Bays (2014)
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.Journal of the American College of Cardiology, 63 23
P. Costanzo, P. Perrone-filardi, E. Vassallo, S. Paolillo, P. Cesarano, G. Brevetti, M. Chiariello (2010)
Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials.Journal of the American College of Cardiology, 56 24
J. Sasaki, Kyosuke Yamamoto, M. Ageta (2002)
Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study.Clinical therapeutics, 24 10
(National Institute for Health and Clinical Excellence. Guidelines [CG181]. Lipid modification: cardiovascular risk and assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. [Online] July 2014 http://www.nice.org.uk/guidance/cg181. Accessed Dec 2014.)
National Institute for Health and Clinical Excellence. Guidelines [CG181]. Lipid modification: cardiovascular risk and assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. [Online] July 2014 http://www.nice.org.uk/guidance/cg181. Accessed Dec 2014.National Institute for Health and Clinical Excellence. Guidelines [CG181]. Lipid modification: cardiovascular risk and assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. [Online] July 2014 http://www.nice.org.uk/guidance/cg181. Accessed Dec 2014., National Institute for Health and Clinical Excellence. Guidelines [CG181]. Lipid modification: cardiovascular risk and assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. [Online] July 2014 http://www.nice.org.uk/guidance/cg181. Accessed Dec 2014.
A. Gotto (2005)
Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.The American journal of cardiology, 96 5A
E. Mills, B. Rachlis, Ping Wu, P. Devereaux, P. Arora, D. Perri (2008)
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.Journal of the American College of Cardiology, 52 22
D. Blom, R. Dent, R. Castro, P. Toth (2016)
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabVascular Health and Risk Management, 12
I. Ford, H. Murray, C. Packard, J. Shepherd, P. Macfarlane, S. Cobbe (2007)
Long-term follow-up of the West of Scotland Coronary Prevention Study.The New England journal of medicine, 357 15
A. Karatasakis, B. Danek, Judit Karacsonyi, B. Rangan, Michele Roesle, T. Knickelbine, M. Miedema, H. Khalili, Z. Ahmad, Shuaib Abdullah, S. Banerjee, E. Brilakis (2017)
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled TrialsJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6
N. Stone, Jennifer Robinson, A. Lichtenstein, C. Noel, B. Merz, D. Lloyd‐Jones, C. Blum, P. Mcbride, R. Eckel, F. Schwartz, A. Goldberg, Susan Shero, Rn, D. Gordon, Sidney Smith, D. Levy, K. Watson, P. Wilson, Karen Eddleman, N. Jarrett, K. Labresh, Lev Nevo, J. Wnek, Jeffrey Anderson, J. Halperin, N. Albert, J. Hochman, B. Bozkurt, R. Kovacs, R. Brindis, Macc Ohman, L. Curtis, S. Pressler, D. DeMets, F. Sellke, R. Guyton, W. Shen, G. Tomaselli, Stone Nj, Robinson J, Lichtenstein Ah, M. Bairey, Blum Cn, Eckel Cb, Goldberg Rh, Gordon Ac, Levy D, Lloyd-Jones Dm, P. Mcbride, Js Schwartz, Shero St, Smith Sc, W. Wilson (2014)
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation, 129 25 Suppl 2
J. Cohen, A. Pertsemlidis, I. Kotowski, R. Graham, C. Garcia, H. Hobbs (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9Nature Genetics, 37
J. Kastelein, F. Akdim, E. Stroes, A. Zwinderman, M. Bots, A. Stalenhoef, F. Visseren, E. Sijbrands, M. Trip, E. Stein, D. Gaudet, R. Duivenvoorden, E. Veltri, A. Marais, E. Groot (2008)
Simvastatin with or without ezetimibe in familial hypercholesterolemia.The New England journal of medicine, 358 14
A. Rossebø, T. Pedersen, K. Boman, P. Brudi, J. Chambers, K. Egstrup, E. Gerdts, C. Gohlke-Bärwolf, I. Holme, Y. Kesäniemi, W. Malbecq, C. Nienaber, S. Ray, T. Skjærpe, K. Wachtell, R. Willenheimer (2008)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.The New England journal of medicine, 359 13
R. Knopp, W. Brown, C. Dujovne, J. Farquhar, E. Feldman, A. Goldberg, S. Grundy, N. Lasser, M. Mellies, R. Palmer, P. Samuel, G. Schonfeld, H. Superko (1987)
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.The American journal of medicine, 83 5B
C. Baigent, A. Keech, P. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 366
P. Koskinen, M. Mänttäri, V. Manninen, J. Huttunen, O. Heinonen, M. Frick (1992)
Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart StudyDiabetes Care, 15
(2016)
Ezetimibe for treating primary heterozygousfamilial and non
A. Arrieta, Jonathan Hong, R. Khera, S. Virani, H. Krumholz, K. Nasir (2017)
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER TrialJAMA Cardiology, 2
V. Tsimihodimos, A. Kakafika, M. Elisaf (2001)
Fibrate treatment can increase serum creatinine levels.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 16 6
(Packard CJ, Ford I, Murray H, McCowan C. Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year follow-up of the West of Scotland Coronary Prevention Study. American Heart Association Scientific Sessions 2014 [Online] November 2014. http://www.medscape.com/viewarticle/835238?nlid=70783_1985&src=wnl_edit_medn_card&spon = 2. Accessed 30 Nov 2014.)
Packard CJ, Ford I, Murray H, McCowan C. Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year follow-up of the West of Scotland Coronary Prevention Study. American Heart Association Scientific Sessions 2014 [Online] November 2014. http://www.medscape.com/viewarticle/835238?nlid=70783_1985&src=wnl_edit_medn_card&spon = 2. Accessed 30 Nov 2014.Packard CJ, Ford I, Murray H, McCowan C. Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year follow-up of the West of Scotland Coronary Prevention Study. American Heart Association Scientific Sessions 2014 [Online] November 2014. http://www.medscape.com/viewarticle/835238?nlid=70783_1985&src=wnl_edit_medn_card&spon = 2. Accessed 30 Nov 2014., Packard CJ, Ford I, Murray H, McCowan C. Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year follow-up of the West of Scotland Coronary Prevention Study. American Heart Association Scientific Sessions 2014 [Online] November 2014. http://www.medscape.com/viewarticle/835238?nlid=70783_1985&src=wnl_edit_medn_card&spon = 2. Accessed 30 Nov 2014.
S. Hayek, Fabrizio Escaro, Assad Sattar, Steven Gamalski, K. Wells, G. Divine, B. Ahmedani, D. Lanfear, M. Pladevall, L. Williams (2013)
Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality.The American journal of cardiology, 111 4
AndrewJ. Coats (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 360
(1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet, 344
A. Vonbank, H. Drexel, S. Agewall, B. Lewis, J. Dopheide, K. Kjeldsen, C. Ceconi, G. Savarese, G. Rosano, S. Wassmann, A. Niessner, T. Schmidt, C. Saely, I. Baumgartner, J. Tamargo (2018)
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a reviewEuropean Heart Journal – Cardiovascular Pharmacotherapy, 4
A. Schmidt, L. Pearce, J. Wilkins, John Overington, A. Hingorani, J. Casas (2017)
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.The Cochrane database of systematic reviews, 4
C. Baigent, M. Landray, C. Reith, J. Emberson, D. Wheeler, C. Tomson, C. Wanner, V. Krane, A. Cass, J. Craig, B. Neal, Lixin Jiang, L. Hooi, A. Levin, L. Agodoa, M. Gaziano, B. Kasiske, R. Walker, Z. Massy, B. Feldt-Rasmussen, U. Krairittichai, V. Ophascharoensuk, B. Fellström, H. Holdaas, V. Tesar, A. Więcek, D. Grobbee, D. Zeeuw, C. Grönhagen‐Riska, T. Dasgupta, D. Lewis, W. Herrington, M. Mafham, W. Majoni, K. Wallendszus, R. Grimm, T. Pedersen, J. Tobert, J. Armitage, A. Baxter, C. Bray, Yiping Chen, Zhengming Chen, M. Hill, C. Knott, S. Parish, D. Simpson, P. Sleight, A. Young, R. Collins (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialLancet, 377
C. Dujovne, M. Ettinger, J. Mcneer, L. Lipka, A. Lebeaut, R. Suresh, Bo Yang, E. Veltri (2002)
Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.The American journal of cardiology, 90 10
L. Bowman, J. Armitage, R. Bulbulia, S. Parish, R. Collins (2007)
Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors.American heart journal, 154 5
G. Savarese, G. Ferrari, G. Rosano, P. Perrone-filardi (2015)
Safety and efficacy of ezetimibe: A meta-analysis.International journal of cardiology, 201
U. Khot, Monica Khot, C. Bajzer, S. Sapp, E. Ohman, S. Brener, S. Ellis, A. Lincoff, E. Topol (2003)
Prevalence of conventional risk factors in patients with coronary heart disease.JAMA, 290 7
N. Seidah (2009)
PCSK9 as a therapeutic target of dyslipidemiaExpert Opinion on Therapeutic Targets, 13
D. Morrone, W. Weintraub, P. Toth, M. Hanson, R. Lowe, Jianxin Lin, Arvind Shah, A. Tershakovec (2012)
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.Atherosclerosis, 223 2
(2000)
The pathophysiology of acute coronary syndromesHeart (British Cardiac Society), 83
C. Stancu, A. Sima (2001)
Statins: mechanism of action and effectsJournal of Cellular and Molecular Medicine, 5
S. Ishikawa, H. Hayashi, K. Kinoshita, M. Abe, Hideyuki Kuroki, R. Tokunaga, S. Tomiyasu, Hideki Tanaka, H. Sugita, T. Arita, Y. Yagi, Masayuki Watanabe, M. Hirota, Hideo Baba (2014)
Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancerInternational Journal of Cancer. Journal International du Cancer, 135
D. Boudreau, Onchee Yu, Jeanene Johnson (2010)
Statin use and cancer risk: a comprehensive reviewExpert Opinion on Drug Safety, 9
S. Yusuf (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. CommentaryThe Lancet, 360
J. Fruchart, P. Duriez (2006)
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.Drugs of today, 42 1
A. Minnich, N. Tian, L. Byan, G. Bilder (2001)
A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscleAmerican Journal of Physiology-endocrinology and Metabolism, 280
A. Keech, D. Colquhoun, James Best, A. Kirby, R. Simes, D. Hunt, W. Hague, E. Beller, M. Arulchelvam, J. Baker, A. Tonkin (2003)
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.Diabetes care, 26 10
(2001)
A potent PPAR alpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscleAm J Physiol Endocrinol Metab, 280
(National Institute for Health and Care Excellence, NICE. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia https://www.nice.org.uk/guidance/ta385/resources/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia-pdf-82602851386309. Updated 2016. Accessed 09/30, 2018)
National Institute for Health and Care Excellence, NICE. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia https://www.nice.org.uk/guidance/ta385/resources/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia-pdf-82602851386309. Updated 2016. Accessed 09/30, 2018National Institute for Health and Care Excellence, NICE. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia https://www.nice.org.uk/guidance/ta385/resources/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia-pdf-82602851386309. Updated 2016. Accessed 09/30, 2018, National Institute for Health and Care Excellence, NICE. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia https://www.nice.org.uk/guidance/ta385/resources/ezetimibe-for-treating-primary-heterozygousfamilial-and-nonfamilial-hypercholesterolaemia-pdf-82602851386309. Updated 2016. Accessed 09/30, 2018
J. Brugts, T. Yetgin, S. Hoeks, A. Gotto, J. Shepherd, R. Westendorp, A. Craen, R. Knopp, H. Nakamura, P. Ridker, R. Domburg, J. Deckers (2009)
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsThe BMJ, 338
A. Pandor, R. Ara, I. Tumur, A. Wilkinson, S. Paisley, A. Duenas, P. Durrington, J. Chilcott (2009)
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trialsJournal of Internal Medicine, 265
J. Shepherd, P. Barter, R. Carmena, P. Deedwania, J. Fruchart, S. Haffner, J. Hsia, A. Breazna, J. Larosa, S. Grundy, D. Waters (2006)
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and DiabetesDiabetes Care, 29
(British National Formulary. 68th ed. UK: BMJ Group and the Royal Pharmaceutical Society of Great Britain; 2014 September.)
British National Formulary. 68th ed. UK: BMJ Group and the Royal Pharmaceutical Society of Great Britain; 2014 September.British National Formulary. 68th ed. UK: BMJ Group and the Royal Pharmaceutical Society of Great Britain; 2014 September., British National Formulary. 68th ed. UK: BMJ Group and the Royal Pharmaceutical Society of Great Britain; 2014 September.
Coronary heart disease (CHD) is the leading cause of mortality worldwide and high low-density lipoprotein (LDL) cholesterol levels have been shown to be key in the pathogenesis of this condition. Lipid control has therefore been the subject of decades of research and has led to many large and robust randomized controlled trials, as well as the highest grossing drug of all time—Lipitor (atorvastatin). Statin therapy has long been indicated for secondary and more recently primary prevention. However, despite the large-scale use of statins, CHD prevalence remains high, and some patients do not respond to statin therapy. There has been a large push to find and test alternative lipid-lowering agents, these include fibrates, cholesterol absorption inhibitors, and proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors. It is the aim of this review to assess the literature surrounding each of these groups of drugs.
Cardiology and Therapy – Springer Journals
Published: Dec 12, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.